Stephen Lam Chan, MD

Transarterial Chemoembolization with Durvalumab or Durvalumab + Bevacizumab in Patients with Locoregional Hepatocellular Carcinoma: EMERALD-1

Purpose: Because curative therapy is not always feasible and there is no standard systemic therapy, patients with intermediate-stage hepatocellular carcinoma (HCC) are treated with locore...

Shukui Qin , MD, PhD;

Zhenggang Ren ;

Joseph Erinjeri ;

Shethah Morgan ;

Gordon Cohen ;

Yasuaki Arai , MD;

Riccardo Lencioni , MD;

Bruno Sangro , MD, PhD;

Stephen Lam Chan , MD;

Masatoshi Kudo , MD, PhD;

10/21/2019

Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240

BackgroundPembro received accelerated approval for second-line therapy in pts with advanced HCC, based on the phase 2, KEYNOTE-224 trial. KEYNOTE-240 was a randomized, phase 3 study of P...

Marcelo Garrido ;

Stephen Lam Chan , MD;

Jennifer J. Knox ;

Bruno Daniele ;

Scot Ebbinghaus ;

Erluo Chen ;

Abby B. Siegel ;

Julien Edeline ;

Baek-Yeol Ryoo ;

Ann-Lii Cheng , MD, PhD;

Philippe Merle ;

Masatoshi Kudo , MD, PhD;

Mohamed Bouattour ;

Richard S. Finn ;

Ho-Yeong Lim ;

Andrew Zhu ;

Valeriy Vladimirovich Breder , MD, PhD;

Yee Chao ;

Sadahisa Ogasawara ;

Thomas Yau ;

07/01/2019

Case Report

Blunt Microdissection and Rotational Atherectomy: An Effective Combination for the Resistant Chronic Total Occlusion

08/01/2008

Paul C. Ho , MD, MSc;

Stephen Lam Chan , MD;

Cyril Leung , MD;

Reported success rates of percutaneous coronary interventions (PCI) of chronic total occlusions (CTO) range from approximately 60–75%,1–3 and are much lower when compared with PCI of nontotal occlusions.4,5 When combined with specialized...

Reported success rates of...

08/01/2008

Journal of Invasive Cardiology

CIO 2020-4 Transarterial Chemoembolization Combined With Durvalumab±Bevacizumab in Patients With Locoregional HCC (EMERALD-1)

Yasuaki Arai , MD;

Zhenggang Ren ;

Joseph Erinjeri ;

Philip He ;

Shethah Morgan ;

Gordon Cohen ;

Riccardo Lencioni , MD;

Bruno Sangro , MD, PhD;

Masatoshi Kudo , MD, PhD;

Stephen Lam Chan , MD;

Shukui Qin , MD, PhD;

07/23/2021

CIO 2023-1 Four-year Overall Survival from the HIMALAYA Study of Tremelimumab + Durvalumab in Unresectable Hepatocellular Carcinoma

Purpose: In the primary analysis (data cut-off: 27 August 2021) of the phase 3 HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Re...

Yoon-Koo Kang , MD, PhD;

Charu Gupta , MSc;

Maria Reig , MD, PhD;

Peter R. Galle , MD, PhD;

Alejandra Negro , PhD;

Masatoshi Kudo , MD, PhD;

Bruno Sangro , MD, PhD;

George Tat-Ming Lau , MBBS, FRACP, MD, PhD;

Valeriy Vladimirovich Breder , MD, PhD;

Stephen Lam Chan , MD;

Robin Kate Kelley , MD;

Wattana Sukeepaisarnjaroen , MD;